SCHEMBL7013205

SCHEMBL7013205

Cc1cc(N2CCNC(CC(=O)N(C)C)C2)ccn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM4 P08173 1/20 0.40
▸ F10 P00742 2/20 0.40
▸ F2 P00734 1/20 0.39
▸ PLAT P00750 1/20 0.39
▸ KLKB1 P03952 1/20 0.39
▸ ADRB1 P08588 6/20 0.38
▸ TLR9 Q9NR96 1/20 0.36
▸ TLR8 Q9NR97 1/20 0.36
▸ TLR7 Q9NYK1 1/20 0.36
▸ PRKCA P17252 1/20 0.35
▸ PRKCQ Q04759 1/20 0.35
▸ PRKCD Q05655 1/20 0.35
▸ AOC3 Q16853 1/20 0.35
▸ NOS2 P35228 1/20 0.34
▸ USP25 Q9UHP3 2/20 0.34
▸ TMEM97 Q5BJF2 1/20 0.34
▸ WNT3A P56704 1/20 0.34
▸ CHRM1 P11229 1/20 0.34
▸ ACACB O00763 1/20 0.34
▸ USP28 Q96RU2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7015232 0.87 CHRM4 (0.42) CHRM4F10ADRB1PRKCAPRKCQ
SCHEMBL7011556 0.86 CHRM4 (0.40) CHRM4F10ADRB1PRKCAPRKCQ
SCHEMBL7012255 0.84 REN (0.42) CHRM4ADRB1PRKCAPRKCQPRKCD
SCHEMBL7015888 0.82 CHRM4 (0.39) CHRM4F10ADRB1PRKCAPRKCQ
SCHEMBL7010873 0.81 CHRM4 (0.38) CHRM4F10F2PLATKLKB1
SCHEMBL7018539 0.76 CHRM4 (0.40) CHRM4F10AOC3TMEM97WNT3A
SCHEMBL7018379 0.71 WNT3A (0.37) CHRM4TLR9TLR8TLR7AOC3
SCHEMBL7013241 0.70 SIGMAR1 (0.42) TMEM97
SCHEMBL2917590 0.68 DPP4 (0.34) —
SCHEMBL20594817 0.68 CHRM4 (0.58) CHRM4F10TMEM97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030187023-A1 Sulfone derivatives, process for their production and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-10-02 — — US disclosed
EP-1302462-A1 SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-04-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187023-A1 Sulfone derivatives, process for their production and use thereof SULT1E1, RRS1, SHH CHRM4 3076/4885F10 717/4885F2 685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback